Aclaris Therapeutics (ACRS) Live Share Price, Invest From India

Aclaris Therapeutics Stock Performance

as on October 3, 2026 at 2:16 pm IST

Day's Low
Day's High
$4.21
Day's Price Range
$4.52
$4.39
4.10%
Downside
2.96%
Upside
52 Week's Low
52 Week's High
$1.74
52-Week Price Range
$6.60
$4.39
60.36%
Downside
50.34%
Upside

Aclaris Therapeutics share price movements today

Previous Close: $4.41
Open: $4.43
Volume: 6.9M
Market Cap: $649.1M
Day's Low - High: $4.21 - $4.52
52 Week Low - High: $1.74 - $6.60

Aclaris Therapeutics Historical Returns

1 Month Return: -26.22 %
3 Month Return: -21.04 %
1 Year Return: + 136.02 %
3 Year Return: -29.87 %
5 Year Return: -74.7 %

Aclaris Therapeutics Stock Fundamentals & Key Indicators

Check Aclaris Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$649.1M

EPS (TTM)

-0.58

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.91

Industry PE ratio

-6.16

PEG Ratio

-0.17

EBITDA

-75.1M

Revenue (TTM)

8.2M

Profit Margin

95.61%

Return On Equity TTM

-61.65%

Aclaris Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aclaris Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Aclaris Therapeutics	StrongBuy	$649.1M	-74.70%	-7.91	95.61%	0.00%
Revolution Medicines	StrongBuy	$44.1B	609.62%	-23.34	0.00%	0.00%
Moderna	Neutral	$75.4B	-44.29%	-24.08	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$132.5B	180.98%	30.19	86.04%	0.00%
Regeneron	Buy	$78.1B	28.80%	17.67	84.86%	0.50%

Stock Returns calculator for Aclaris Therapeutics Stock including INR - Dollar returns

The Aclaris Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Aclaris Therapeutics investment value today

Current value as on today

₹2,56,187

Returns

₹1,56,187

(+156.19%)

Returns from Aclaris Therapeutics Stock

₹1,36,022 (+136.02%)

Dollar Impact

₹20,165 (+20.17%)

Analyst Recommendation on Aclaris Therapeutics Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for Aclaris Therapeutics. Average target price of $10.18

Aclaris Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Aclaris Therapeutics.

What analysts predicted

56.88%UPSIDE

Target Price

$10.18

Current Price

$4.39

Analyzed by

4 Analysts

High

$16

Target

$10.18

Low

$10

Aclaris Therapeutics target price $10.18, a slight upside of 56.88% compared to current price of $4.39. According to 4 analysts rating.

Indian Investors' Interest in Aclaris Therapeutics Stock

Search interest for Aclaris Therapeutics Stock has decreased by -4% in the last 30 days, reflecting a downward trend in search activity.

Time period: September 3, 2026 to October 3, 2026

Change:-4% versus previous 30 day period

Aclaris Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	2	2	4	9	1	1	3	1	1	1
Gross Profit	0	0	1	0	0	0	2	2	1	1
Operating Income	-18	-12	-10	-99	-18	-18	-17	-22	-22	-24
EBITDA	-15	-12	-9	-13	-17	-16	-14	-19	-19	-21
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-16	-10	-7	-96	-15	-15	-14	-19	-19	-21
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-16	-10	-7	-96	-15	-15	-14	-19	-19	-21
Net Profit Margin	23.27%	30.98%	44.59%	-0.98%	65.22%	-4.11%	83.69%	162.01%	80.21%	85.82%

Aclaris Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	1	10	4	6	6	29	31	18	7
Gross Profit	0	3	0	1	2	17	13	15	5
Operating Income	-72	-135	-111	-50	-89	-89	-97	-141	-76
EBITDA	-53	-80	-90	-47	-64	-84	-115	-51	-64
Interest Expense	-	-	-	-	-	-	-	-	-
Depreciation	0	1	1	1	0	0	0	0	0
Income Before Tax	-70	-132	-113	-51	-90	-86	-88	-132	-64
Income Tax Expense	-1	2	-	0	-	-	0	-	-
Net Income	-68	-132	-161	-51	-90	-86	-88	-132	-64
Net Profit Margin	28.28%	32.12%	4.07%	20.81%	30.29%	59.80%	42.14%	85.09%	73.28%

Aclaris Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-16	-10	-7	-96	-15	-15	-14	-19	-19	-21
Operating Cash Flow	-20	-12	22	-8	-13	-9	-10	-13	-18	-19
Investing Cash Flow	16	0	2	-88	19	5	13	10	-30	10
Financing Cash Flow	0	0	0	74	0	0	-3	-2	57	0
Change in Cash	-4	-13	24	-23	5	-4	0	-5	8	-9

Aclaris Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-68	-132	-113	-51	-90	-86	-88	-132	-64
Operating Cash Flow	-54	-100	-96	-38	-52	-67	-78	-20	-47
Investing Cash Flow	-55	9	105	6	-167	12	46	-69	48
Financing Cash Flow	100	128	-30	18	225	72	26	74	-5
Change in Cash	-9	36	-21	-13	5	17	-5	-15	-4

Global Institutional Holdings in Aclaris Therapeutics

Check out the Institutions with significant holdings in Aclaris Therapeutics.

Funds	Holdings
Peter Kolchinsky	8.64%
Vanguard	4.89%
iShares	4.10%
VANGUARD INDEX FUNDS	3.44%
Michael Rockefeller	1.09%

See all

Insights on Aclaris Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 3 years, Revolution Medicines, Inc. Common Stock has given 84.3% return, outperforming this stock by 114.2%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 430.9%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 4 quarters, -14.61M → -21.50M (in $), with an average decrease of 14.7% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 1.99M → 1.62M (in $), with an average decrease of 18.4% per quarter
NEGATIVE IMPACT
Price Dip
In the last 7 days, ACRS stock has moved down by -14.8%

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.

Organisation	Aclaris Therapeutics
Headquarters	640 Lee Road, Wayne, PA, 19087, US
Industry	Biotechnology
CEO	Neal S. Walker

Key Management of Aclaris Therapeutics

Name	Title
Dr. Neal S. Walker D.O., M.D.	Co-Founder, CEO & Chairman
Mr. William C. Roberts	Senior Vice President of Corporate Communications & Investor Relations
Dr. Jesse W. Hall M.D.	Chief Medical Officer
Dr. Hugh M. Davis Ph.D.	President, COO & Director
Mr. Kevin Balthaser	Chief Financial Officer
Mr. James Loerop	Chief Business Officer
Dr. Roland Kolbeck Ph.D.	Chief Scientific Officer
Mr. Matthew Rothman J.D.	General Counsel & Corporate Secretary
Mr. Steve Tucker	Executive Vice President of Project Leadership
Ms. Nina Samra M.S.	Senior Vice President of Clinical Operations

FAQs

What is Aclaris Therapeutics share price today?

Aclaris Therapeutics share price today is $4.39 as on October 3, 2026 at 8:46 am IST at the close of the market. Aclaris Therapeutics share today touched a day high of $4.52 and a low of $4.21.

What is the 52 week high and 52 week low for Aclaris Therapeutics share?

Aclaris Therapeutics share touched a 52 week high of $6.60 on August 25, 2026 and a 52 week low of $1.74 on October 14, 2025. Aclaris Therapeutics stock price today i.e. October 3, 2026 at 8:46 am IST is closed at $4.39,which is 33.48% down from its 52 week high and 152.30% up from its 52 week low.

What is Aclaris Therapeutics's market capitalisation today?

Aclaris Therapeutics market capitalisation is $0.00T as on October 3, 2026 at 8:46 am IST.

How to invest in Aclaris Therapeutics Stock (ACRS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Aclaris Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Aclaris Therapeutics Stock (ACRS) from India?

Indian investors can start investing in Aclaris Therapeutics (ACRS) shares with as little as ₹96.300003051758 or $1 (as of October 3, 2026 at 10:44 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Aclaris Therapeutics stock (as per the Rupee-Dollar exchange rate as on October 3, 2026 at 10:44 am IST). Based on Aclaris Therapeutics share’s latest price of $4.39 as on October 3, 2026 at 8:46 am IST, you will get 2.2779 shares of Aclaris Therapeutics. Learn more about fractional shares .

What are the returns that Aclaris Therapeutics has given to Indian investors in the last 5 years?

Aclaris Therapeutics stock has given -74.7% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?